In a recent post on the IVI-sponsored Health Affairs featured blog series, Ian Spatz outlines the challenges facing new FDA commissioner Scott Gottlieb. Among the challenges identified are the determination of new criteria for the control of medical information and the encouragement of competition to control drug costs.

Read the full article here.

About the Health Affairs/IVI Featured Blog Series: Drugs and Medical Innovation — In partnership with Health Affairs, IVI is proud to sponsor the “Drugs and Medical Innovation” blog series. On an ongoing basis, articles in this series will explore topics such as value-based reimbursement, drug policy and pricing, balancing short-term access against long-term rates of innovation, and other relevant issues. Our goal is to create an open forum for sharing ideas and debating issues in these areas, extending the discussion to a broader audience.